I'll say; I was expecting +/- 55c on the back of the US DoD writing a blank cheque to get this drug over the finish line.
Then +/- 80c upon further positive results of PCSK9 inhibitor proof of concept study in June/July.
When you consider the sheer lack of shares available to the public if even just one of these drugs reaches the market... It's retirement stock on the dividends alone.
